All In Biotech

Drug Trial Radar · NCT05808374

Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B

Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B

Last checked: Nov 20, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

85

Planned (sponsor's estimate)

Start

Apr 30, 2023

Primary completion

May 31, 2024

Study completion May 31, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5635 in healthy adults and chronic hepatitis B. To explore the reasonable dosage of HRS-5635.

Conditions

  • Chronic Hepatitis B

Interventions

  • HRS-5635Drug

    50mg HRS-5635;100mg HRS-5635;200mg HRS-5635;400mg HRS-5635;600mg HRS-5635;800mg HRS-5635

  • HRS-5635Drug

    100mg HRS-5635,Q4W;200mg HRS-5635 ,Q4W;400mg HRS-5635,Q4W;200mg HRS-5635, Q2W

  • HRS-5635Drug

    200mg HRS-5635,Q4W

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events In Part 1Time frame: 85 days
  2. Number of Adverse Events In Part 2Time frame: 169 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of China University of Science and Technology

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.